Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | APAF1 | O14727 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364091 | 1.00 | AXL (0.50) | AXLMAPK1PSMD14GRM4MEN1 | |
| SCHEMBL18418498 | 0.78 | PSMD14 (0.41) | AXLMAPK1PSMD14GRM4HTT | |
| SCHEMBL19100792 | 0.75 | GRM4 (0.54) | PSMD14GRM4MEN1KMT2AMAPT | |
| SCHEMBL13978041 | 0.75 | PSMD14 (0.48) | PSMD14GRM4MEN1KMT2AMAPT | |
| SCHEMBL369216 | 0.75 | PSMD14 (0.48) | PSMD14GRM4MAPTKDM4ETP53 | |
| SCHEMBL2066259 | 0.75 | PSMD14 (0.48) | PSMD14GRM4KMT2AMAPTKDM4E | |
| SCHEMBL3175822 | 0.75 | PSMD14 (0.48) | PSMD14GRM4MEN1KMT2AMAPT | |
| SCHEMBL31307015 | 0.75 | PSMD14 (0.48) | PSMD14GRM4MEN1KMT2AMAPT | |
| SCHEMBL22510135 | 0.75 | PSMD14 (0.48) | PSMD14GRM4MAPTKDM4ETP53 | |
| SCHEMBL2053968 | 0.75 | PSMD14 (0.48) | MAPK1PSMD14GRM4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035365-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-05 | — | — | US | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4565584-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-06-11 | — | — | EP | disclosed |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2025-03-20 | — | — | US | disclosed |
| WO-2025021120-A1 | 5-HT2A RECEPTOR AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| WO-2024028316-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-02-08 | — | — | WO | disclosed |
| US-20230391752-A1 | PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES | CHULALONGKORN UNIVERSITY (TH) | 2023-12-07 | — | — | US | disclosed |
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-7964728-B2 | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-06-21 | — | — | US | disclosed |
| US-20110053962-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. | 2011-03-03 | — | — | US | disclosed |
| US-20110053962-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. | 2011-03-03 | — | — | US | disclosed |
| US-20110021543-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS PESTICIDES | NOVARTIS AG (CH) | 2011-01-27 | — | — | US | disclosed |
| WO-2010033980-A2 | 4-AZAINDOLE BISPHOSPHONATES | ISIS INNOVATION LTD. (GB) | 2010-03-25 | — | — | WO | disclosed |
| EP-2152716-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS PESTICIDES | Novartis Ag (CH) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008135442-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS PESTICIDES | NOVARTIS AG (CH) | 2008-11-13 | — | — | WO | disclosed |
| US-20080009514-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | ABBVIE B.V. (NL) | 2008-01-10 | — | — | US | disclosed |
| US-20080009514-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | ABBVIE B.V. (NL) | 2008-01-10 | — | — | US | disclosed |
| WO-2008003736-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYLCHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391752-A1 | PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES | GLS2, PYGL, CPS1 | AXL 2669/4885MAPK1 4156/4885PSMD14 4016/4885 |
| US-20110021543-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS PESTICIDES | DDT, TYR, CAT | AXL 767/4885MAPK1 4441/4885PSMD14 3382/4885 |
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | AXL 4258/4885MAPK1 3224/4885PSMD14 3135/4885 |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | AXL 4226/4885MAPK1 3357/4885PSMD14 3094/4885 |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | AXL 3932/4885MAPK1 3135/4885PSMD14 2947/4885 |
| US-20080009514-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | CHRNA5, CHRNA7, CHRNA2 | AXL 2667/4885MAPK1 3199/4885PSMD14 4586/4885 |
| US-20110053962-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | CHRNA5, CHRNA7, CHRNA2 | AXL 2584/4885MAPK1 3065/4885PSMD14 4508/4885 |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | AXL 4226/4885MAPK1 3357/4885PSMD14 3094/4885 |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | AXL 3932/4885MAPK1 3135/4885PSMD14 2947/4885 |
| US-20260035365-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | AXL 105/4885MAPK1 79/4885PSMD14 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.